Biomarkers Consortium – Bone Quality Project
The Problem Patients with osteoporosis, other bone diseases or increased risk for bone fractures have diminished bone strength and quality,...Biomarkers Consortium Cancer Steering Committee Immuno-Oncology Working Group
The Biomarkers Consortium (BC) is issuing a Request For Proposals (RFP) for novel biomarker development to support the mission of the BC Can...Biomarkers Consortium – Sarcopenia 2
The FNIH Biomarkers Consortium Sarcopenia 2 project, Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability, r...Pre-competitive Analytical Validation of SV2A PET as a Biomarker of Synaptic Density (SV2A PET Project)
The Problem Although researchers have established biomarkers to diagnose Alzheimer’s disease, no biomarker can track cognitive decline ...Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE)
The Problem Patients at risk of developing non-alcoholic steatohepatitis (NASH) do not present with symptoms until the disease has advanced...Biomarkers Consortium – Neurofilament as a Blood-Based Biomarker of Neurodegeneration in Familial Frontotemporal Degeneration (FTD)
The Problem The earliest stages of FTD are hard to detect until the disease has progressed and damage is more permanent. Experts believe th...Biomarkers Consortium – Measurable residual disease in acute myeloid leukemia (MRD in AML)
The Problem Detection of measurable residual disease (MRD) is a strong predictor of relapse in acute and chronic leukemia, but its integrat...Biomarkers Consortium – Longitudinal Proteomic Changes in CSF from ADNI: Towards Better Defining the Trajectory of Prodromal and Early Alzheimer’s Disease
The Problem Alzheimer’s disease (AD)Researchers lack the tools needed to diagnose pre-symptomatic and early disease, and to predict how/a...Diseases
Learn more about the diseases we fight
Partner With Us
Work with the FNIH to accelerate medical breakthroughs for patients